Trastuzumab (T) plus oral vinorelbine (OV) in patients with advanced breast cancer (ABC) overexpressing Her2/neu

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [31] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS, 2010, 10 (21) : 3800 - 3810
  • [32] Proteomic characterization of Her2/neu-overexpressing breast cancer cells
    Chen, Hexin
    Pimienta, Genaro
    Gu, Yiben
    Sun, Xu
    Hu, Jianjun
    Kim, Min-Sik
    Chaerkady, Raghothama
    Gucek, Marjan
    Cole, Robert N.
    Sukumar, Saraswati
    Pandey, Akhilesh
    PROTEOMICS CLINICAL APPLICATIONS, 2011, 5 (3-4) : 201 - 201
  • [33] Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    Stemmler, H. J.
    Kahlert, S.
    Siekiera, W.
    Untch, M.
    Heinrich, B.
    Heinemann, V.
    BREAST, 2006, 15 (02): : 219 - 225
  • [34] Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
    Disis, Mary L.
    Wallace, Danelle R.
    Gooley, Theodore A.
    Dang, Yushe
    Slota, Meredith
    Lu, Hailing
    Coveler, Andrew L.
    Childs, Jennifer S.
    Higgins, Doreen M.
    Fintak, Patricia A.
    dela Rosa, Corazon
    Tietje, Kathleen
    Link, John
    Waisman, James
    Salazar, Lupe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4685 - 4692
  • [35] Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study
    Ales-Martinez, Jose E.
    Balmana, Judith
    Sanchez-Rovira, Pedro
    Bofill, Francisco Javier Salvador
    Garcia-Saenz, Jose Angel
    Pimentel, Isabel
    Murillo, Serafin Morales
    Fernandez, Adela
    Martinez, Ainhara Lahuerta
    Ferrer, Neus
    Zamora, Pilar
    Bermejo, Begona
    Diaz-Redondo, Tamara
    Lopez-Ceballos, Maria Helena
    Galan, Maria
    Malfettone, Andrea
    Calabuig, Laura
    Sampayo-Cordero, Miguel
    Perez-Garcia, Jose Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2023, 83 (05)
  • [36] A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
    Angeli, Eurydice
    Paris, Justine
    Le Tilly, Olivier
    Desvignes, Celine
    Gapihan, Guillaume
    Boquet, Didier
    Pamoukdjian, Frederic
    Hamdan, Diaddin
    Rigal, Marthe
    Poirier, Florence
    Lutomski, Didier
    Azibani, Feriel
    Mebazaa, Alexandre
    Herbet, Amaury
    Mabondzo, Aloise
    Falgarone, Geraldine
    Janin, Anne
    Paintaud, Gilles
    Bousquet, Guilhem
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [37] A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer
    Menyhart, Otilia
    Santarpia, Libero
    Gyorffy, Balazs
    CURRENT CANCER DRUG TARGETS, 2015, 15 (08) : 665 - 683
  • [38] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    Burstein, HJ
    Kuter, I
    Campos, SM
    Gelman, RS
    Tribou, L
    Parker, LM
    Manola, J
    Younger, J
    Matulonis, U
    Bunnell, CA
    Partridge, AH
    Richardson, PG
    Clarke, K
    Shulman, LN
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2722 - 2730
  • [39] Phase II Study of Vinorelbine Plus Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes
    Kwon, H.
    Oh, S. Y.
    Kim, S. H.
    Lee, S.
    Lee, J. H.
    Kim, H. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S353 - S353
  • [40] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
12345